The effect of antiperspirant and deodorant use on acute radiation dermatitis in breast cancer patients during radiotherapy: a systematic review and meta-analysis.
Antiperspirant
Breast cancer
Deodorant
Radiotherapy
Skin care
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
23
11
2022
accepted:
22
02
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
While some authors have investigated the impact of antiperspirant /deodorant on the development of acute radiation dermatitis (RD) among patients undergoing radiotherapy (RT) for breast cancer, recommendations supporting the use of antiperspirant/deodorant during breast RT remain highly variable. This systematic review and meta-analysis aims to evaluate the evidence investigating the effect of antiperspirant/deodorant on the development of acute RD during post-operative breast RT. A literature search has been performed using OVID MedLine, Embase, and Cochrane databases (1946 to September 2020) to identify randomized controlled trials (RCTs) that have investigated deodorant/antiperspirant use during RT. The meta-analysis was conducted using RevMan 5.4 to calculate pooled effect sizes and 95% confidence intervals (CI). Five RCTs met the inclusion criteria. The use of antiperspirant/deodorant did not significantly affect the incidence of grade (G) 1 + RD (OR 0.81, 95% CI 0.54-1.21, p = 0.31). Prohibition of deodorant use did not significantly prevent the occurrence of G2 + acute RD (OR 0.90, 95%, CI 0.65-1.25, p = 0.53). No significant effect was reported in preventing G3 RD between the antiperspirant/deodorant and control groups (OR 0.54, 95%, CI 0.26-1.12, p = 0.10). There was no significant difference in pruritus and pain between patients undergoing skin care protocols with or without antiperspirant/deodorant (OR 0.73, 95% CI 0.29, 1.81, p = 0.50, and OR 1.05, 95% CI 0.43-2.52, p = 0.92, respectively). The use of antiperspirant/deodorant during breast RT does not significantly affect the incidence of acute RD, pruritus, and pain. As such, the current evidence does not support recommendation against antiperspirant/deodorant use during RT.
Identifiants
pubmed: 36867303
doi: 10.1007/s00520-023-07657-y
pii: 10.1007/s00520-023-07657-y
doi:
Substances chimiques
Antiperspirants
0
Deodorants
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387
doi: 10.3322/caac.21387
pubmed: 28055103
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8 . (Erratum in: Lancet. 2014 Nov 22;384(9957):1848)
doi: 10.1016/S0140-6736(14)60488-8
Beadle BM, Woodward WA, Tucker SL et al (2009) Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734–744. https://doi.org/10.1016/j.ijrobp.2008.04.078
doi: 10.1016/j.ijrobp.2008.04.078
pubmed: 18707822
Atun R, Jaffray DA, Barton MB et al (2015) Expanding global access to radiotherapy. Lancet Oncol 16(10):1153–1186. https://doi.org/10.1016/S1470-2045(15)00222-3
doi: 10.1016/S1470-2045(15)00222-3
pubmed: 26419354
Borras JM, Barton M, Grau C et al (2015) The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 116(1):45–50. https://doi.org/10.1016/j.radonc.2015.04.021
doi: 10.1016/j.radonc.2015.04.021
pubmed: 26002304
Kole AJ, Kole L, Moran MS (2017) Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer Targets Therapy 9:313–323. https://doi.org/10.2147/BCTT.S109763
doi: 10.2147/BCTT.S109763
pubmed: 28503074
pmcid: 5426474
Allali S, Kirova Y (2021) Radiodermatitis and fibrosis in the context of breast radiation therapy: a critical review. Cancers (Basel) 13(23):5928. https://doi.org/10.3390/cancers13235928
doi: 10.3390/cancers13235928
pubmed: 34885037
Dahn HM, Boersma LJ, de Ruysscher D et al (2021) The use of bolus in postmastectomy radiation therapy for breast cancer: a systematic review. Crit Rev Oncol Hematol 163:103391. https://doi.org/10.1016/j.critrevonc.2021.103391
doi: 10.1016/j.critrevonc.2021.103391
pubmed: 34102286
Ramseier JY, Ferreira MN, Leventhal JS (2020) Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Womens Dermatol 6(5):349–356. https://doi.org/10.1016/j.ijwd.2020.07.015
doi: 10.1016/j.ijwd.2020.07.015
pubmed: 33898697
pmcid: 8060663
Théberge V, Harel F, Dagnault A (2009) Use of axillary deodorant and effect on acute skin toxicity during radiotherapy for breast cancer: a prospective randomized noninferiority trial. Int J Radiat Oncol Biol Phys 75(4):1048–1052. https://doi.org/10.1016/j.ijrobp.2008.12.046
doi: 10.1016/j.ijrobp.2008.12.046
pubmed: 19327906
Cumming J, Routsis D (2009) Are improvements needed in the management of severe acute skin reactions following completion of breast radiotherapy? A discussion of some possible service options. J Radiother Pract 8(1):11–16. https://doi.org/10.1017/S146039690800650X
doi: 10.1017/S146039690800650X
Gee A, Moffitt D, Churn M, Errington R (2000) A randomised controlled trial to test a non-metallic deodorant used during a course of radiotherapy. J Radiother Pract 1(4):205–212. https://doi.org/10.1017/S1460396999000321
doi: 10.1017/S1460396999000321
Bennett C (2009) An investigation into the use of a non-metallic deodorant during radiotherapy treatment: a randomised controlled trial. J Radiother Pract 8(1):3–9. https://doi.org/10.1017/S146039690800647X
doi: 10.1017/S146039690800647X
Watson LC, Gies D, Thompson E, Thomas B (2012) Randomized control trial: evaluating aluminum-based antiperspirant use, axilla skin toxicity, and reported quality of life in women receiving external beam radiotherapy for treatment of Stage 0, I, and II breast cancer. Int J Radiat Oncol Biol Phys 83(1):e29-34. https://doi.org/10.1016/j.ijrobp.2011.12.006
doi: 10.1016/j.ijrobp.2011.12.006
pubmed: 22516385
Lewis L, Carson S, Bydder S et al (2014) Evaluating the effects of aluminum-containing and non-aluminum containing deodorants on axillary skin toxicity during radiation therapy for breast cancer: a 3-armed randomized controlled trial. Int J Radiat Oncol Biol Phys 90(4):765–771. https://doi.org/10.1016/j.ijrobp.2014.06.054
doi: 10.1016/j.ijrobp.2014.06.054
pubmed: 25194668
Finkelstein S, Kanee L, Behroozian T et al (2022) Comparison of clinical practice guidelines on radiation dermatitis: a narrative review. Support Care Cancer 30(6):4663–4674. https://doi.org/10.1007/s00520-022-06829-6
doi: 10.1007/s00520-022-06829-6
pubmed: 35067732
Wong RK, Bensadoun RJ, Boers-Doets CB et al (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 21(10):2933–2948. https://doi.org/10.1007/s00520-013-1896-2
doi: 10.1007/s00520-013-1896-2
pubmed: 23942595
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Guyatt GH, Oxman AD, Vist GE, GRADE Working Group et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–6. https://doi.org/10.1136/bmj.39489.470347.AD
doi: 10.1136/bmj.39489.470347.AD
pubmed: 18436948
pmcid: 2335261
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49(7):749–754. https://doi.org/10.1016/0895-4356(96)00019-4
doi: 10.1016/0895-4356(96)00019-4
pubmed: 8691224
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C
doi: 10.1016/0360-3016(95)00060-C
pubmed: 7713792
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v.30: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–81. https://doi.org/10.1016/S1053-4296(03)00031-6
doi: 10.1016/S1053-4296(03)00031-6
pubmed: 12903007
Hardefeldt PJ, Edirimanne S, Eslick GD (2012) Deodorant use and the risk of skin toxicity in patients undergoing radiation therapy for breast cancer: a meta-analysis. Radiother Oncol 105(3):378–379. https://doi.org/10.1016/j.radonc.2012.08.020
doi: 10.1016/j.radonc.2012.08.020
pubmed: 22995589
Graham PH, Graham JL (2009) Use of deodorants during adjuvant breast radiotherapy: a survey of compliance with standard advice, impact on patients and a literature review on safety. J Med Imaging Radiat Oncol 53(6):569–573. https://doi.org/10.1111/j.1754-9485.2009.02125.x
doi: 10.1111/j.1754-9485.2009.02125.x
pubmed: 20002290
Post M, Hughes A, Mitchell A et al (2018) Symptom management guidelines: radiation dermatitis. Available from: http://www.bccancer.bc.ca/nursingsite/Documents/16.%20Radiation%20Dermatitis.pdf
Gosselin T, Ginex PK, Backler C et al (2020) ONS Guidelines™ for Cancer Treatment-Related Radiodermatitis. Oncol Nurs Forum 47(6):654–670. https://doi.org/10.1188/20.ONF.654-670
doi: 10.1188/20.ONF.654-670
pubmed: 33063779
Bennet C (2020) The Society and College of Radiographers practice guideline document radiation dermatitis guidelines for radiotherapy healthcare professionals. The Society of Radiographers
Johnston P (2018) Evidence based recommendations for the assessment and management of radiation-induced skin toxicities in breast cancer. Part 5. Management of long-term effects [Internet]. CancerCare Manitoba. Available from: https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/.galle//ries/files/treatment-guidelines-rro-files/practice-guidelines/supportive-care/Part_5_Management_of_LongTerm_Effects.pdf . Accessed 17 Feb 2022
Johnston P (2018) Evidence based recommendations for the assessment and management of radiation-induced skin toxicities in breast cancer. Part 4. Management of acute radiation-induced skin toxicities [Internet]. CancerCare Manitoba. Available from: https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/.galleries/files/treatment-guidelines-rro-files/practice-guidelines/supportive-care/Part_4_Management_of_Acute_Radiation-Induced_Skin_Toxicities.pdf . Accessed 17 Feb 2022
Marta GN, Coles C, Kaidar-Person O et al (2020) The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: a critical review. Crit Rev Oncol Hematol 156:103090. https://doi.org/10.1016/j.critrevonc.2020.103090.J
doi: 10.1016/j.critrevonc.2020.103090.J
pubmed: 33091800
pmcid: 7448956
Haviland JS, Owen JR, Dewar JA, START Trialists’ Group et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://doi.org/10.1016/S1470-2045(13)70386-3
doi: 10.1016/S1470-2045(13)70386-3
pubmed: 24055415
Murray Brunt A, Haviland JS, Wheatley DA, FAST-Forward Trial Management Group et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395(10237):1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6
doi: 10.1016/S0140-6736(20)30932-6
pubmed: 32580883
pmcid: 7262592
Meattini I, Marrazzo L, Saieva C et al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol 38(35):4175–4183. https://doi.org/10.1200/JCO.20.00650
doi: 10.1200/JCO.20.00650
pubmed: 32840419
Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1(7):931–941. https://doi.org/10.1001/jamaoncol.2015.2666
doi: 10.1001/jamaoncol.2015.2666
pubmed: 26247543
pmcid: 4635441